Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00978458 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
A Phase 3 study of Brain and Central Nervous System Tumors and Neurotoxicity, sponsored by Eastern Cooperative Oncology Group.
- Active
- Registry status
- Phase 3
- Development phase
- 540
- Enrollment target
- 20
- Study locations
NCT00978458 is a Phase 3 study of Brain and Central Nervous System Tumors and Neurotoxicity that is active but no longer recruiting, run by Eastern Cooperative Oncology Group. The registered enrollment target is 540 participants, above the 172-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (214% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT00978458, a Phase 3 study of Brain and Central Nervous System Tumors and Neurotoxicity, is active but no longer recruiting, sponsored by Eastern Cooperative Oncology Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 540 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective when given together with or without temozolomide in treating patients with low-grade glioma. PURPOSE: This randomized phase III trial is studying radiation therapy so see how well it works when given together with or without temozolomide in treating patients with low-grade glioma.
Conditions Studied
Interventions
- DRUG temozolomide
- RADIATION intensity-modulated radiation therapy
- RADIATION 3-dimensional conformal radiation therapy
Study Locations (20)
Colorado
- Aurora Presbyterian Hospital - Aurora
- St. Anthony Central Hospital - Denver
- Porter Adventist Hospital - Denver
- Presbyterian - St. Luke's Medical Center - Denver
- St. Joseph Hospital - Denver
- CCOP - Colorado Cancer Research Program - Denver
- Swedish Medical Center - Englewood
- Sky Ridge Medical Center - Lone Tree
Illinois
- Illinois CancerCare - Bloomington - Bloomington
- St. Joseph Medical Center - Bloomington
- Graham Hospital - Canton
California
- Rebecca and John Moores UCSD Cancer Center - La Jolla
- Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center - Orange
Florida
- Mayo Clinic - Jacksonville - Jacksonville
- Florida Hospital Cancer Institute at Florida Hospital Orlando - Orlando
Alabama
- UAB Comprehensive Cancer Center - Birmingham
Arizona
- Arizona Oncology Services Foundation - Phoenix
Connecticut
- Eastern Connecticut Hematology and Oncology Associates - Norwich
Delaware
- CCOP - Christiana Care Health Services - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2009-11-17 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00978458
The ClinicalTrials.gov registry entry for NCT00978458 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 540 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 172-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (214% higher). The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 3 interventions - of which temozolomide is the first listed.
NCT00978458 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Colorado, Illinois, California.
Frequently Asked Questions
What is clinical trial NCT00978458 about?
NCT00978458 is a clinical study titled "Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma". RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as temozolomide, work in different w...
What is the current status of trial NCT00978458?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 540 participants. The study started on 2009-11-17. Estimated completion is 2026-12-31.
What conditions does trial NCT00978458 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors, Neurotoxicity.
What interventions are being tested in trial NCT00978458?
The interventions under investigation include: temozolomide (DRUG), intensity-modulated radiation therapy (RADIATION), 3-dimensional conformal radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00978458?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00978458 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)
ACTIVE NOT RECRUITING · Phase 3
-
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
ACTIVE NOT RECRUITING · Phase 3
-
SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme
COMPLETED · Phase 3
-
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
COMPLETED · Phase 3
-
Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas
COMPLETED · Phase 3
-
Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.